Echo Therapeutics announced publication of results from three pilot clinical studies of its Symphony Transdermal Continuous Glucose Monitoring (tCGM) System in the Journal of Diabetes Science and Technology. The article highlights that each of the three pilot clinical studies produced positive results supporting the use of Echo's Symphony(TM) tCGM System for reliable, non-invasive, real-time
continuous glucose monitoring, and its most recently developed skin permeation device, the Prelude(TM) SkinPrep System.
"The data from our pilot feasibility studies to date support our late-stage development programs of our Symphony tCGM System for use in diabetes and hospital markets," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We have made substantial progress with Symphony over the past nine months. This article emphasizes that progress and the potential of our Symphony System to assist diabetics and healthcare professionals to improve glycemic control and reduce the rate of short- and long-term complications."
"Tight glycemic control through continuous glucose monitoring is essential for patients in diverse settings, including for both diabetics at home and hospitalized patients in critical care conditions," said Stanley Nasraway, M.D., Director of Surgical Intensive Care Units at Tufts Medical Center, Principal Investigator and corresponding author of the published studies. "The Symphony tCGM System, with continuing development, offers a potentially safe and efficacious option that is non-invasive and easy to use in both settings."